Although the role of IL-10 in AML needs to be clarified, the addition of immunomodulatory agents that block the IL-10 and PD-1 signaling pathways may be an interesting approach for the treatment of AML, but only in selected patients, probably in combination with other agents. The gene discussed is PDCD1; the disease is acute myeloid leukemia.